Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction

Area of Science:

• Molecular Biology
• Cancer Biology
• Drug Discovery

Background:

• Myeloid cell leukemia 1 (MCL-1) is a key factor in cancer development and chemoresistance.
• Clinical use of MCL-1 inhibitors is limited by toxic side effects.
• MCL-1's complex biology involves multiple isoforms and poorly understood non-apoptotic functions.

Purpose of the Study:

• To investigate the non-apoptotic roles of MCL-1 in cancer cells.
• To explore the therapeutic potential and limitations of MCL-1 inhibition beyond apoptosis.
• To identify novel interacting partners of MCL-1 involved in DNA integrity.

Main Methods:

• Genetic deletion and pharmacologic inhibition of MCL-1.
• Assessment of DNA damage and cell proliferation.
• Proteomic profiling to identify interacting protein complexes.

Main Results:

• MCL-1 targeting induces DNA damage and retards cell proliferation, irrespective of the mitochondrial apoptotic pathway.
• Cancer cell susceptibility to MCL-1 inhibitors aligns with anti-proliferative rather than pro-apoptotic drug profiles.
• Proteomic analysis identified the minichromosome maintenance (MCM) complex as a nuclear interactor of MCL-1.

Conclusions:

• MCL-1 plays a significant role in DNA integrity and cell-cycle progression, extending beyond its known apoptotic functions.
• MCL-1 inhibitors may have broader therapeutic applications, including in combination therapies, but require careful management of toxicity.
• The identification of the MCM complex provides a new mechanistic link between MCL-1 and DNA maintenance.